SIREN : 512622820
DEVELOPPEMENT FILIERES BIO is a French company founded 17 years ago, specialized in the sector Ingénierie, études techniques. Based in RENNES (35000), this company of category ETI shows in 2024 a revenue of 679 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 679 168 € | 589 191 € | 522 834 € | 481 410 € | 915 651 € | 686 354 € | 494 880 € | 685 910 € | 466 521 € |
| Net income | 1 277 061 € | 447 166 € | -150 275 € | 231 924 € | 468 601 € | 353 622 € | 72 281 € | 286 734 € | 42 957 € |
| EBITDA | 539 060 € | 415 720 € | 379 030 € | 322 964 € | 743 733 € | 429 982 € | 316 351 € | 513 444 € | 291 835 € |
| Net margin | 188.0% | 75.9% | -28.7% | 48.2% | 51.2% | 51.5% | 14.6% | 41.8% | 9.2% |
In 2024, DEVELOPPEMENT FILIERES BIO achieves revenue of 679 k€. Revenue is growing positively over 9 years (CAGR: +4.8%). Vs 2023, growth of +15% (589 k€ -> 679 k€). After deducting consumption (0 €), gross margin stands at 679 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 539 k€, representing 79.4% of revenue. Positive scissor effect: EBITDA margin improves by +8.8 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.3 M€, i.e. 188.0% of revenue. This profit can be retained or distributed to shareholders.
679 168 €
679 168 €
539 060 €
1 221 488 €
1 277 061 €
79.4%
The debt ratio (= Financial debt / Equity x 100) stands at 66%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 59%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 9.2 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 37.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
66.455%
59.172%
37.274%
9.221
In 2024, the debt ratio of DEVELOPPEMENT FILIERES BIO (66.45) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of DEVELOPPEMENT FILIERES BIO (59.2%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of DEVELOPPEMENT FILIERES BIO (9.22) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 820.58. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 56.4x. Operating income very largely covers interest expenses: high safety margin.
820.579
56.356
In 2024, the liquidity ratio of DEVELOPPEMENT FILIERES BIO (820.58) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of DEVELOPPEMENT FILIERES BIO (56.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 69 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 63 days. The company must finance 6 days of gap between collections and payments. Overall, WCR represents 286 days of revenue, i.e. 540 k€ to permanently finance.
539 782 €
69 j
63 j
0 j
286 j
Indicative estimate only : the number of comparable transactions in this sector is limited (40 transactions). This range of 151 165€ to 1 730 699€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 40 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare DEVELOPPEMENT FILIERES BIO with other companies in the same sector:
Voir toutes les statistiques du secteur Ingénierie, études techniques
The revenue of DEVELOPPEMENT FILIERES BIO in 2024 is 679 k€.
Yes, DEVELOPPEMENT FILIERES BIO generated a net profit of 1.3 M€ in 2024.
The headquarters of DEVELOPPEMENT FILIERES BIO is located in RENNES (35000), in the department Ille-et-Vilaine.
The tax return of DEVELOPPEMENT FILIERES BIO is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
DEVELOPPEMENT FILIERES BIO operates in the sector Ingénierie, études techniques (NAF code 71.12B). See the 'Sector positioning' section above to compare the company with its competitors.